JAGX - Jaguar Health Inc Operating income before deduction of amortization

Brandmark of jaguar.health (JAGX)

The absolute EBITDA level demonstrates the impact of exclusive rights to Mytesi, with the parameter stabilizing at 0.00. Profit growth is based on attracting botanical medicine experts through RSU shares. Stability of pharmacy supplies is ensured by strict climate control during the transportation of plant components. Analysis of this chart helps assess the real return from the core operations of Jaguar Health, Inc. (JAGX).

Jaguar Health Inc - JAGX Profit before payment of interest, taxes and amortization (period 11/23/2025 - 11/15/2026)

Jaguar Health Inc (JAGX) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Rate Chart Jaguar Health, Inc.|JAGX - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Jaguar Animal Health|JAGX - Real Price to Acquire Entire Company
- balance sheet equity data:
Book Price of a Share Jaguar Health|JAGX - Company Book Value|Market Cap to Book Value Multiple jaguar.health|JAGX - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Capital Jaguar Health, Inc.|JAGX - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Jaguar Health, Inc.|JAGX - Company Total Debt|Debts to Book Capitalization Jaguar Health, Inc.|JAGX - Company Long-Term Debts|Company Short-Term Debts Jaguar Health|Intermediate Coverage Ratio jaguar.health
- financial results and valuation multiples details:
JAGX - Net Income|Expected Net Income Jaguar Health, Inc.|JAGX - P/E Multiple|Future Price to Earnings Multiple Jaguar Health|JAGX - PEG Multiple|Company Value to EBITDA Jaguar Health, Inc.|JAGX - Operating profit EBITDA|Net earnings per share (EPS TTM) Jaguar Health|JAGX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months jaguar.health|JAGX - Net earnings per share growth this year|Projected earnings per share increase next year Jaguar Health, Inc.
- sales and revenue data:
JAGX - Revenue and Sales Volume|Company Future Revenue Jaguar Health|JAGX - Market Cap to Revenue|Forward Price to Sales Jaguar Health, Inc.|JAGX - Sales Growth YoY (TTM)
Fundamental company valuation:JAGX (Jaguar Health, Inc.)
Original product of Jaguar Health

This metric reflects net cash flow from operating activities, excluding the impact of taxes, interest, and depreciation and amortization to assess real operational efficiency. By analyzing the EBITDA figure as of the current date, an investor determines the ability of Jaguar Health, Inc. (JAGX) to finance the transition to ethical sourcing of botanical components and the implementation of environmental regulations without resorting to external borrowing.

Who Jaguar Health, Inc. competes with

Operating profit before depreciation charges Phathom Pharmaceuticals|Terns Pharma - Operating profit EBITDA|Operating income before deduction of amortization Ironwood Pharma IRWD|CURX (curanexpharma.com) - Operating profit before deduction of amortization|IMRN: Company profit before taxes, interest and amortization|EVOK (Evoke Pharma Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization enterothera.com ENTO|Operating profit EBITDA RDHL|Operating profit EBITDA palisadebio.com (PALI)|Profit before payment of interest, taxes and amortization bioratherapeutics.com BIOR|Income before deduction of interest, taxes and amortization MORF